AG011 will begin Phase III trials in the treatment of ulcerative colitis soon.

SynCo Bio Partners completed the manufacture and release of ActoGeniX’ drug substance AG011 for use in a Phase II clinical trial with ulcerative colitis patients.

ActoGeniX is focused on the development and commercialization of ActoBiotics™, a novel class of protein-based biopharmaceuticals that reportedly can be orally administered.

To provide the AG011 drug product required for the Phase II studies, due to start this summer, SynCo developed and scaled up the manufacturing process involving cultivation, purification, and lyophilization of AG011.

Previous articleQiagen and Geneart Partner to Develop and Commercialize Protein Production Product
Next articlePoniard Exercises Option to License Kinase Inhibitors from Scripps